secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001171843-22-007291
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex reports Q3 2022 net loss of $26.8M; cash $323.5M; barzolvolimab data readouts planned
--------------------------------------------------------------------------------

- Net loss per share ($0.57) in Q3 2022 vs ($0.45) in Q3 2021; nine-month net loss ($85.8M) includes $15M litigation settlement.
- Revenue $0.4M in Q3, down from $0.2M in Q3 2021; R&D expenses rose to $21.6M on barzolvolimab trial and manufacturing.
- Cash, cash equivalents and marketable securities $323.5M as of Sept 30, 2022; management says sufficient through 2025.
- Phase 2 barzolvolimab studies in CSU, CIndU ongoing; 12-week data from Phase 1b CSU due Feb 2023; CIndU cohort data expected Dec 2022.
- CDX-585 (ILT4 & PD-(L)1 bispecific) expected to enter clinic in 2023; CDX-527 (PD-L1 & CD27) discontinued due to evolving competitive landscape and internal hurdles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184322007291/0001171843-22-007291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184322007291/f8k_110922.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer